Search Results 2371-2380 of 25430 for oral
This phase II trial studies how well giving ruxolitinib phosphate (oral JAK inhibitor INCB18424) works in treating patients with relapsed or refractory diffuse ...
Oral and Maxillofacial Surgery · Orthopedic Oncology · Orthopedic Surgery · Otolaryngology (ENT)/Head and Neck Surgery. P. Pain Medicine · Pain Rehabilitation ...
Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...
Staff skilled in dozens of specialties work together to ensure quality care and successful recovery. Departments that treat this condition. Oral and ...
2014. Cum Laude Award - Oral PresentationSociety of Computed Body Tomography & Magnetic Resonance. 2013. Certificate of MeritRadiological Society of North ...
... oral anticoagulants are a newer class of oral medications that are widely prescribed. Due to the relative novelty of the medication class, unintended ...
Oral prednisone dose > 10 mg per day (or of an alternative corticosteroid at a dose higher than that equipotent to prednisone 10 mg per day) OR oral ...
... oral agents are not eligible; Patients with known hypersensitivity to any TZD oral agents are not eligible; Eastern Cooperative Oncology Group (ECOG) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.